The purpose of this study is to determine whether or not people with schizophrenia who take
LY2140023 become physically dependent on it, and experience a series of symptoms such as
craving to have the drug when they stop using it.
This trial consists of two phases: An open-label phase consisting of up to 4 weeks and a
double-blind phase consisting of up to 3 weeks.